Sana D Karam, Jacob Gadwa, Justin Yu, Miles Piper, Michael W Knitz, Laurel B Darragh, Nicholas A Olimpo, Sophia Corbo, Brooke Neupert, Jessica I Beynor, Alexander Nguyen, Chloe Hodgson, Khalid Nady Mohammed Abdelazeem, Diemmy Nguyen, Anthony Saviola, Mudita Pincha, Christian Klein, Maria Amann
{"title":"肿瘤微环境的内在特征决定了对放射免疫疗法的不同反应","authors":"Sana D Karam, Jacob Gadwa, Justin Yu, Miles Piper, Michael W Knitz, Laurel B Darragh, Nicholas A Olimpo, Sophia Corbo, Brooke Neupert, Jessica I Beynor, Alexander Nguyen, Chloe Hodgson, Khalid Nady Mohammed Abdelazeem, Diemmy Nguyen, Anthony Saviola, Mudita Pincha, Christian Klein, Maria Amann","doi":"10.1101/2024.09.06.611679","DOIUrl":null,"url":null,"abstract":"Background: Treatment with immunotherapy can elicit varying responses across cancer types, and the mechanistic underpinnings that contribute to response vs. progression remain poorly understood. However, to date there are few preclinical models that accurately represent these disparate disease scenarios.\nMethods: Using combinatorial radio-immunotherapy consisting of PD-1 blockade, IL2Rβγ biased signaling, and OX40 agonism we were able to generate preclinical tumor models with conflicting responses, where head and neck squamous cell carcinoma (HNSCC) models responds and pancreatic ductal adenocarcinoma (PDAC) progresses.\nResults: By modeling these disparate states, we find that regulatory T cells (Tregs) are expanded in PDAC tumors undergoing treatment, constraining tumor reactive CD8 T cell activity. Consequently, the depletion of Tregs restores the therapeutic efficacy of our treatment and abrogates the disparity between models. Moreover, we show that through heterotopic implantations that the site of tumor development defines the response to therapy, as implantation of HNSCC tumors into the pancreas resulted in comparable levels of tumor progression.\nConclusions: This work highlights complexity of combining immunotherapies within the tumor microenvironment and further defines the immune and non-immune components of the tumor microenvironment as an intrinsic feature of immune suppression.","PeriodicalId":501182,"journal":{"name":"bioRxiv - Immunology","volume":"73 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment\",\"authors\":\"Sana D Karam, Jacob Gadwa, Justin Yu, Miles Piper, Michael W Knitz, Laurel B Darragh, Nicholas A Olimpo, Sophia Corbo, Brooke Neupert, Jessica I Beynor, Alexander Nguyen, Chloe Hodgson, Khalid Nady Mohammed Abdelazeem, Diemmy Nguyen, Anthony Saviola, Mudita Pincha, Christian Klein, Maria Amann\",\"doi\":\"10.1101/2024.09.06.611679\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Treatment with immunotherapy can elicit varying responses across cancer types, and the mechanistic underpinnings that contribute to response vs. progression remain poorly understood. However, to date there are few preclinical models that accurately represent these disparate disease scenarios.\\nMethods: Using combinatorial radio-immunotherapy consisting of PD-1 blockade, IL2Rβγ biased signaling, and OX40 agonism we were able to generate preclinical tumor models with conflicting responses, where head and neck squamous cell carcinoma (HNSCC) models responds and pancreatic ductal adenocarcinoma (PDAC) progresses.\\nResults: By modeling these disparate states, we find that regulatory T cells (Tregs) are expanded in PDAC tumors undergoing treatment, constraining tumor reactive CD8 T cell activity. Consequently, the depletion of Tregs restores the therapeutic efficacy of our treatment and abrogates the disparity between models. Moreover, we show that through heterotopic implantations that the site of tumor development defines the response to therapy, as implantation of HNSCC tumors into the pancreas resulted in comparable levels of tumor progression.\\nConclusions: This work highlights complexity of combining immunotherapies within the tumor microenvironment and further defines the immune and non-immune components of the tumor microenvironment as an intrinsic feature of immune suppression.\",\"PeriodicalId\":501182,\"journal\":{\"name\":\"bioRxiv - Immunology\",\"volume\":\"73 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"bioRxiv - Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.09.06.611679\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"bioRxiv - Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.06.611679","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:使用免疫疗法治疗不同类型的癌症会产生不同的反应,而导致反应与进展的机理基础仍然鲜为人知。然而,迄今为止,很少有临床前模型能准确代表这些不同的疾病情况:方法:使用由 PD-1 阻断、IL2Rβγ 偏倚信号传导和 OX40 激动组成的组合放射免疫疗法,我们能够生成具有相互冲突反应的临床前肿瘤模型,其中头颈部鳞状细胞癌(HNSCC)模型有反应,而胰腺导管腺癌(PDAC)有进展:通过模拟这些不同的状态,我们发现接受治疗的 PDAC 肿瘤中调节性 T 细胞(Tregs)会扩大,从而限制肿瘤反应性 CD8 T 细胞的活性。因此,Tregs的消耗恢复了我们治疗的疗效,并消除了模型之间的差异。此外,我们通过异位移植证明,肿瘤发生的部位决定了对治疗的反应,因为将 HNSCC 肿瘤移植到胰腺会导致肿瘤进展水平相当:这项工作凸显了在肿瘤微环境中结合免疫疗法的复杂性,并进一步明确了肿瘤微环境中的免疫和非免疫成分是免疫抑制的内在特征。
Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment
Background: Treatment with immunotherapy can elicit varying responses across cancer types, and the mechanistic underpinnings that contribute to response vs. progression remain poorly understood. However, to date there are few preclinical models that accurately represent these disparate disease scenarios.
Methods: Using combinatorial radio-immunotherapy consisting of PD-1 blockade, IL2Rβγ biased signaling, and OX40 agonism we were able to generate preclinical tumor models with conflicting responses, where head and neck squamous cell carcinoma (HNSCC) models responds and pancreatic ductal adenocarcinoma (PDAC) progresses.
Results: By modeling these disparate states, we find that regulatory T cells (Tregs) are expanded in PDAC tumors undergoing treatment, constraining tumor reactive CD8 T cell activity. Consequently, the depletion of Tregs restores the therapeutic efficacy of our treatment and abrogates the disparity between models. Moreover, we show that through heterotopic implantations that the site of tumor development defines the response to therapy, as implantation of HNSCC tumors into the pancreas resulted in comparable levels of tumor progression.
Conclusions: This work highlights complexity of combining immunotherapies within the tumor microenvironment and further defines the immune and non-immune components of the tumor microenvironment as an intrinsic feature of immune suppression.